Tutar H E, Kansu A, Kalayci A G, Girgin N, Atalay S, Imamoğlu A
Department of Pediatric Cardiology, Ankara University Medical School, Turkey.
Acta Paediatr. 2000 Jul;89(7):820-3.
Life-threatening ventricular dysrhythmias mainly attributed to QTc prolongation have been reported in adults and children who were using cisapride, a prokinetic agent that facilitates gastrointestinal motility. Recent adult and paediatric case reports have suggested an association of malignant ventricular dysrhythmias with administration of cisapride in conjunction with drugs that inhibit its cytochrome P-450 metabolism. Therefore, to analyse the time- and dose-related effects of cisapride on ventricular repolarization, we prospectively studied infants and children receiving cisapride with no concomitant medications. Standard 12-lead resting ECGs were obtained from 38 patients (mean age: 6.6 +/- 4.4 y) before the first dose of cisapride (0.8-1.2 mg/kg/d) therapy, and 3 d, 7 d and 1 mo after the first dose of continuing cisapride therapy. The corrected QT interval (QTc), dispersion of QT and QTc (QTD, QTcD) were calculated. Patients were divided into two groups according to dose of cisapride: Group 1 (n = 22) (0.8 mg/kg/d), Group 2 (n = 16) (1.2 mg/ kg/d). Data obtained from these patients were compared with a control group consisting of 372 normal children. No clinical adverse effects such as palpitations, presyncope or syncope were noted during the study. Baseline QTc, QTD and QTcD measurements of the study group were not different from those of the control group. Mean QTc values of the study group on days 7 and 30 of cisapride therapy were found to be significantly higher than those of the control group (p < 0.001 and <0.0001, respectively). Mean QTc values of the study group on days 7 and 30 of therapy were also significantly higher than those of baseline value (p < 0.01 and <0.001, respectively). Mean QTD and mean QTcD values that were recorded throughout the cisapride treatment in the study group were not found to be different from the baseline values and the values of the controls. Mean QTD and QTcD were also not found to be different between Groups 1 and 2. However, mean QTc was found to be more significantly increased from baseline at the first month of therapy in Group 2 (p < 0.05). The results of this study suggest that cisapride treatment cause prolongation of ventricular repolarization without causing increased heterogeneity of repolarization (QT dispersion). However, the clinical significance of this effect is unclear, because all the patients in this study group remained asymptomatic, without signs of dysrhythmia.
据报道,使用西沙必利(一种促进胃肠蠕动的促动力药物)的成人和儿童出现了主要归因于QTc延长的危及生命的室性心律失常。近期的成人和儿科病例报告表明,恶性室性心律失常与西沙必利联合使用抑制其细胞色素P - 450代谢的药物有关。因此,为了分析西沙必利对心室复极的时间和剂量相关影响,我们对未同时服用其他药物的接受西沙必利治疗的婴幼儿和儿童进行了前瞻性研究。在首次给予西沙必利(0.8 - 1.2mg/kg/d)治疗前、首次给予西沙必利持续治疗后3天、7天和1个月,从38例患者(平均年龄:6.6±4.4岁)获取标准12导联静息心电图。计算校正QT间期(QTc)、QT和QTc离散度(QTD、QTcD)。根据西沙必利剂量将患者分为两组:第1组(n = 22)(0.8mg/kg/d),第2组(n = 16)(1.2mg/kg/d)。将这些患者的数据与由372名正常儿童组成的对照组进行比较。研究期间未观察到心悸、先兆晕厥或晕厥等临床不良反应。研究组的基线QTc、QTD和QTcD测量值与对照组无差异。发现西沙必利治疗第7天和第30天研究组的平均QTc值显著高于对照组(分别为p < 0.001和<0.0001)。治疗第7天和第30天研究组的平均QTc值也显著高于基线值(分别为p < 0.01和<0.001)。研究组在整个西沙必利治疗过程中记录的平均QTD和平均QTcD值与基线值及对照组的值无差异。第1组和第2组之间的平均QTD和QTcD也无差异。然而,发现第2组在治疗第1个月时平均QTc较基线值增加更为显著(p < 0.05)。本研究结果表明,西沙必利治疗可导致心室复极延长,但不会导致复极不均一性增加(QT离散度)。然而,这种效应的临床意义尚不清楚,因为本研究组所有患者均无症状,无心律失常迹象。